title: Neuroleptic malignant syndrome associated with risperidone and olanzapine in first-episode schizophrenia.
abstract: This case report describes an 18-year-old African American male who presented to a state psychiatric facility with symptoms of bizarre behavior, delusions and auditory hallucination. He was diagnosed with schizophrenia and treated with eight days of risperidone followed by five days of olanzapine. During this two-week period, this patient began to develop signs and symptoms of neuroleptic malignant syndrome (NMS). Two weeks after all neuroleptic medications were discontinued, all his vital signs and labs returned to baseline. This case report and others from literature suggest that risperidone and olanzapine may induce NMS in some patients.
authors.affiliation: Department of Behavioral Medicine and Psychiatry, West Virginia University, Morgantown, USA.
authors.forename: Ahmed
authors.initials: A
authors.lastname: Aboraya
authors.forename: Jennifer
authors.initials: J
authors.lastname: Schumacher
authors.forename: Ehab
authors.initials: E
authors.lastname: Abdalla
authors.forename: James
authors.initials: J
authors.lastname: LePage
authors.forename: Melanie
authors.initials: M
authors.lastname: McGhee
authors.forename: Deborah
authors.initials: D
authors.lastname: Butcher
authors.forename: Holly
authors.initials: H
authors.lastname: Griffin
authors.forename: Mohammed
authors.initials: M
authors.lastname: Shahda
mesh_terms: D000293:Adolescent; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001569:Benzodiazepines; D006801:Humans; D008297:Male; D009459:Neuroleptic Malignant Syndrome / Q000175:diagnosis / Q000209:etiology*; D000077152:Olanzapine; D010890:Pirenzepine / Q000009:adverse effects* / Q000031:analogs & derivatives*; D018967:Risperidone / Q000009:adverse effects*; D012559:Schizophrenia / Q000188:drug therapy*
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D010890:Pirenzepine; D018967:Risperidone; D000077152:Olanzapine